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http://dx.doi.org/10.1016/j.ccell.2015.03.004SUMMARYCancer immunotherapies under development have generally focused on either stimulating T cell immunity or
driving antibody-directed effector functions of the innate immune system such as antibody-dependent cell-
mediated cytotoxicity (ADCC). We find that a combination of an anti-tumor antigen antibody and an untar-
geted IL-2 fusion protein with delayed systemic clearance induces significant tumor control in aggressive
isogenic tumor models via a concerted innate and adaptive response involving neutrophils, NK cells, macro-
phages, and CD8+ T cells. This combination therapy induces an intratumoral ‘‘cytokine storm’’ and extensive
lymphocyte infiltration. Adoptive transfer of anti-tumor T cells together with this combination therapy leads to
robust cures of established tumors and development of immunological memory.INTRODUCTION
The compelling promise of immunotherapies is to counter
heterogeneously mutating tumors with the adaptive immune
response. In particular, the benefits of combining multiple
therapies are particularly appealing (van Elsas et al., 1999;
Overwijk, 2005; Stagg et al., 2007). One of the earliest
such combinations tested was the cytokine interleukin-2
(IL-2) together with monoclonal antibodies against tumor
antigens.Significance
Weekly intravenous administration of two proteins—an ant
extended serum half-life—significantly increases tumor infiltra
and controls the growth of aggressive isogenic tumors. Our wo
action from both adaptive and innate immunity to achieve durAntibodies such as trastuzumab, rituximab, and cetuximab
have achieved tremendous clinical successes (Weiner et al.,
2009), and their capability to enlist innate effector functions is a
critical component of their therapeutic efficacy (Ferris et al.,
2010). In mechanistic studies in xenograft mouse models, innate
effector cells expressing activating FcgR, particularly natural
killer (NK) cells, have been shown to be required for the thera-
peutic efficacy of monoclonal antibodies (Clynes et al., 2000;
Sliwkowski et al., 1999), and lymphoma patients expressing
higher-affinity alleles of FcgRIII responded better to rituximabi-tumor antigen antibody and an IL-2 fusion protein with
tion of neutrophils, NK cells, macrophages, and CD8+ T cells
rk supports a paradigm of stimulating concerted anti-tumor
able tumor control.
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therapy (Weng and Levy, 2003), consistent with a major
contribution of antibody-dependent cell-mediated cytotoxicity
(ADCC) to antibody therapy. Encouragingly, cell culture bioassay
studies have demonstrated that IL-2 enhanced NK cell activity
against antibody-coated tumor cells (Carson et al., 2001; Eisen-
beis et al., 2004). Unfortunately, these results did not translate
clinically because such combinations consistently failed to
provide significant clinical benefits over antibody alone (Khan
et al., 2006; Mani et al., 2009; Poire´ et al., 2010).
T cells play an unexpectedly critical role in anti-tumor antigen
antibody therapy, although their importance is often not
observed because of studies being performed in immunodefi-
cient mice. In studies of antibody therapy in immunocompetent
mice with isogenic tumors, therapeutic effects vanish when
CD8+ T cells are depleted (Abe`s et al., 2010; Dyall et al., 1999;
Park et al., 2010; Stagg et al., 2011; Vasovic et al., 1997; Wang
et al., 2012). We imagined that IL-2 treatment might be exploited
to amplify monoclonal antibody therapy not simply via the previ-
ously assumed NK-mediated ADCC but also by boosting the
CD8+ T cell adaptive response because IL-2 exerts significant
pleiotropic effects on regulatory, helper, and cytolytic memory
T cells (Liao et al., 2013).
However, given the poor clinical results of combining IL-2 with
monoclonal antibodies, we hypothesized that the signaling re-
sulting from parenteral IL-2 administration may be temporally
limited because IL-2 is rapidly cleared when administered intra-
venously in bolus doses (Konrad et al., 1990), leading to highly
oscillatory cytokine exposure. The cellular response to such
IL-2 spikes can be dramatically different than the response to
more stable concentration trajectories (Rao et al., 2005). Both
the duration and strength of IL-2 signaling determine the balance
between effector andmemory cytolytic T cell development (Feau
et al., 2011; Kalia et al., 2010; Pipkin et al., 2010), a balance crit-
ical to the success of immunotherapies such as adoptive cell
therapy (June, 2007). It is noteworthy that, in previous clinical tri-
als combining IL-2 and antibodies, IL-2 was administered as a
subcutaneous low-dose pulse either once per day (Mani et al.,
2009; Poire´ et al., 2010) or three times per week (Khan et al.,
2006). Consequently, these patients’ T cells were exposed to
short bursts of IL-2 signaling. Therefore, we sought to develop
a means by which sufficiently sustained IL-2 signaling could be
provided so that simultaneous dosing with an anti-tumor antigen
monoclonal antibody might provide the synergistic therapeutic
effect that has so far remained elusive.
RESULTS
Extending IL-2 Serum Exposure via Multiple Injections
To explore the effects of differing IL-2 exposure combined with a
monoclonal antibody targeting a tumor antigen, we first treated
established B16F10melanomawith IL-2 or the anti-TYRP-1 anti-
body TA99. TYRP-1 is a melanocyte marker that becomes
surface-expressed on B16F10. With infrequent IL-2 exposure,
neither agent, dosed separately or together, provided survival
benefits (Figure 1A). However, when extended daily dosing was
performed, a notable synergistic effect was observed when
TA99 was added, significantly extending survival (Figure 1B).
Despite this promising response, daily IL-2 dosing resulted in
poor body condition for many of the treated mice (data not490 Cancer Cell 27, 489–501, April 13, 2015 ª2015 Elsevier Inc.shown), and such a regimen could be arduous and expensive
for clinical translation. Therefore, we sought to achieve similar
synergistic effects through a form of IL-2 that provides similar
long-term IL-2 exposure but requires fewer and smaller doses.
Extending IL-2 Circulation Lifetime via Fc Fusion
To increase the persistence of IL-2 exposure in vivo, we fused
wild-type murine IL-2 to the fragment crystallizable (Fc) region
of murine immunoglobulin G2a (IgG2a), termed Fc/IL-2 (Fig-
ure S1A). We introduced the D265A mutation to the Fc—shown
previously to abrogate FcgR binding and complement activation
(Baudino et al., 2008)—to eliminate cytotoxic effects on the IL-
2R+ cells we wished to stimulate. We chose a monovalent heter-
odimeric form of the fusion protein to avoid avidity effects from
two IL-2 molecules on the same protein. Fc/IL-2 possessed a
similar specific bioactivity as murine IL-2 produced either from
E. coli or the clinical drug Proleukin (Figure S1B). Fc/IL-2 demon-
strated an increase in serum duration, with a b half-life nearly
three times that of wild-type murine IL-2 (Figure S1C; Table
S1). Fc/IL-2 exhibited significant degradation after in vitro incu-
bation in serum at 37C for 48 hr (Figure S1D).
Fc/IL-2 and TA99 Synergize to Control B16F10 Growth
We proceeded to evaluate the efficacy of Fc/IL-2 against estab-
lished B16F10 tumors and its potential synergismwith TA99. Co-
horts were administered equimolar Fc/IL-2 to that of the IL-2
given in the infrequent exposure case with identical dosing
schedules. Impressively, administration of Fc/IL-2 with TA99
(Fc/IL-2+TA99) resulted in a strong synergy between the two
agents that fully controlled B16F10 growth during treatment,
extending survival further than either single agent (Figure 1C).
The dosing of Fc/IL-2+TA99 appeared well tolerated by the
mice, which continued to gain weight during treatment (Fig-
ure S1E) and showed no changes in pulmonary wet weight (Fig-
ure S1F), although splenomegaly (Figure S1G) and an acute
increase in the serum level of liver enzymes (Figure S1H) and
various inflammatory cytokines (Figure S1I) were observed.
To confirm that the synergistic efficacy was solely due to the
serum half-life extension of Fc/IL-2 as opposed to immunolog-
ical effects conferred by the Fc region, we fused IL-2 to mouse
serum albumin (MSA/IL-2) to generate an alternative form of
IL-2 with an extended serum half-life (Figure S1C; Table S1)
and bioactivity (Figure S1B) because albumin is similarly re-
cycled by FcRn (Anderson et al., 2006). MSA/IL-2+TA99 and
Fc/IL-2+TA99 were essentially identical in efficacy (Figure 1D),
suggesting that any form of IL-2 with an increased serum
half-life, or perhaps a continuous infusion of IL-2, will exhibit
this synergistic therapeutic effect.
We further tested three additional tumor models with three
different monoclonal antibodies to demonstrate the generaliz-
ability of this strategy: (1) D5-HER2melanoma in hmHER2 trans-
genic mice (Wang et al., 2012) using Fc/IL-2 and trastuzumab
(Herceptin) (Figure 2A); (2) RM9 prostate cancer (Baley et al.,
1995) in C57BL/6 mice using Fc/IL-2 and 3F8 monoclonal anti-
body (mAb) (Zhang et al., 1998), a murine IgG3 antibody target-
ing the GD2 antigen expressed on RM9 (Figure 2B); and (3)
Ag104A fibrosarcoma in C3H/HeN mice using Fc/IL-2 and 237
mAb, a murine IgG2a targeting the OTS8 antigen found on
Ag104A (Ward et al., 1989; Figure 2C).
Figure 1. Extended Serum Half-Life IL-2
Combined with a Tumor-Specific Antibody
Controls Tumor Growth
(A–D) Tumor growth and survival curves of C57BL/
6 mice bearing subcutaneous B16F10 tumors
treated with (A) PBS, murine IL-2, and/or TA99; (B)
PBS, Proleukin, and/or TA99; (C) PBS, Fc/IL-2,
and/or TA99; and (D) PBS, Fc/IL-2+TA99, or MSA/
IL-2+TA99. Arrows indicate points of treatment.
n = 5/group. *p < 0.05, **p < 0.01 versus the
corresponding color group in the legend. Data are
mean ± SEM.
See also Figure S1 and Table S1.In every case, the combination of Fc/IL-2 with an anti-tumor
IgG showed superior efficacy to either agent alone, even where
the antibody itself provided no benefits (Figure 2). Therefore, the
strong tumor-suppressive effect is generalized to four different
tumor models with a unique anti-tumor antigen and antibody
pairing plus a serum-persistent form of IL-2.
Fc/IL-2+TA99 Promotes Effector Cell Infiltration
We hypothesized that the strong control of tumor growth
observed was due to a combination of adaptive and innate im-
mune activation localized to the tumor microenvironment. H&E
staining of tumor sections from mice treated with either Fc/IL-2
or TA99 alone showed some lymphocyte infiltration restricted
to the edges (Figures S2Ab and S2Ac). However, Fc/IL-Cancer Cell 27, 489–52+TA99 treatment resulted in brisk
lymphocyte infiltration both at the periph-
ery (Figure S2Ad) and within the tumor
mass (Figure S2B) as well as widespread
necrosis (Figure S2C). Additionally, we
observed instances of direct lymphocyte
engagement with a tumor cell (Fig-
ure S2B). Similarly, immunofluorescence
of tumor sections showed robust infiltra-
tion of these immune cells (Figure 3A).
It has been reported previously that the
presence of briskly infiltrating lympho-
cytes is a favorable prognostic indicator
in melanoma (Clemente et al., 1996).
This apt observation prompted us to
further identify and quantify infiltrating
effector cells using flow cytometry.
The CD3+CD8+ T cell population was
increased significantly more than 10-fold
with Fc/IL-2 or Fc/IL-2+TA99 (Figure 3B).
The CD3+CD4+ T cell and CD3+CD4+
CD25+FoxP3+ regulatory T (Treg) cell pop-
ulation were elevated with all three treat-
ment groups (Figure 3B). As expected
of an IL-2-based therapy, the increase
in Treg cells was proportional to that of
CD8+ T cells because the ratio of these
two cells was unaffected (Figure S2D).
The CD3NK1.1+ NK cell population
was also increased significantly morethan 5-fold with Fc/IL-2 or Fc/IL-2+TA99 (Figure 3B). Interest-
ingly, an increase in the CD11b+Ly-6C+Ly-6G+ neutrophil
population was unique to the combination of Fc/IL-2+TA99 (Fig-
ure 3B), and only Fc/IL-2+TA99 showed a statistically significant
difference in the CD11b+F4/80+ macrophage population relative
to the PBS-treated control (Figure 3B).
We next sought to determine the contribution of distinct effec-
tors to therapeutic efficacy through antibody-mediated deple-
tions, where confirmation of systemic depletion was obtained
using samples from the spleen, blood, or peritoneal cavity
(Figure S2E). CD8+ T cell depletion, neutrophil depletion, or NK
cell depletion all attenuated therapeutic efficacy, suggesting
an important role for each of these cell types in controlling
tumor growth (Figure 3C). Depletion of the tumor-resident01, April 13, 2015 ª2015 Elsevier Inc. 491
Figure 2. Extended Serum Half-Life IL-2
Combined with a Tumor-Specific Antibody
Is Generalizable
(A) Tumor growth and survival curves of hmHER2
Tg mice bearing subcutaneous D5-HER2 tumors
treated with PBS, Fc/IL-2, and/or Herceptin.
n = 10/group.
(B) Tumor growth and survival curves of C57BL/6
mice bearing subcutaneous RM9 tumors treated
with PBS, Fc/IL-2, and/or 3F8 mAb. n = 5/group.
(C) Tumor growth and survival curves of C3H mice
bearing subcutaneous Ag104A tumors treated
with PBS, Fc/IL-2, and/or 237 mAb. n = 5/group.
*p < 0.05, **p < 0.01, ****p < 0.0001 versus the
corresponding color group in the legend. Data are
mean ± SEM.CD11b+F4/80+ macrophage population by an anti-CSF-1R anti-
body had no apparent effect on the efficacy of the treatment (Fig-
ure S2F). Nevertheless, this population might simultaneously
contribute to and hinder the therapeutic effect via a mix of ‘‘M1
anti-tumor’’ or ‘‘M2 pro-tumor’’ macrophages, respectively. To
briefly investigate this, we looked at themacrophage polarization
through the ratio of CD206 andmajor histocompatibility complex
class II (MHC-II) expression (Gabrilovich et al., 2012), indicative
of macrophages tending toward M2 or M1 polarization, respec-
tively. This ratio was slightly lower in Fc/IL-2+TA99-treated tu-
mors but not statistically significant (Figure S2G).
Fc/IL-2+TA99 Promotes an Intratumoral Cytokine Storm
with NK Cells Inducing Macrophage-Derived MIP-2
Given the extensive intratumoral immune cell infiltration with
Fc/IL-2+TA99, we explored changes in intratumoral cytokine
and chemokine levels induced by these infiltrating effector cells
through multiplex Luminex assays. Nearly all cytokines and
chemokines measured exhibited significant increases in intratu-
moral concentration when tumor-bearing mice were treated with
Fc/IL-2+TA99 relative to PBS (Figure 4A). The set of elevated cy-
tokines observed in our system broadly overlaps with those seen
in the clinical presentation of a ‘‘cytokine storm’’ (Suntharalin-
gam et al., 2006; Winkler et al., 1999), indicative of a broad and
strong immune activation within the tumor. The CXCR2 ligand
MIP-2 (CXCL2) showed a striking increase of nearly 40-fold (Fig-492 Cancer Cell 27, 489–501, April 13, 2015 ª2015 Elsevier Inc.ure 4A), an observation consistent with
the observed increase in neutrophil infil-
tration (Figure 3B), because MIP-2 is
a powerful neutrophil attractant (Wolpe
et al., 1989).
We next wished to understand how the
antibody TA99 was able to drastically
improve themild efficacy of Fc/IL-2 alone.
Fc/IL-2 or Fc/IL-2+TA99 induced nearly
equivalent intratumoral levels of many
different cytokines and chemokines, but
there were eight different cytokines and
chemokines that appeared to be elevated
in the tumor only with Fc/IL-2+TA99 treat-
ment (Figure 4B, blue). These included in-
flammatory cytokines such as IL-6, IL-1a,and IL-1b but also neutrophil-related factors such as granulocyte
colony-stimulating factor (G-CSF) and MIP-2 (Figure 4B). These
results further suggest the importance of neutrophils in the
therapeutic efficacy of Fc/IL-2+TA99 and highlight that this syn-
ergistic effect is only achieved with the two agents together.
To further understand which cells might be mediating these
different cytokines, we monitored changes in intratumoral cyto-
kine and chemokine levels when specific effector cells were
depleted. CD8+ T cells, NK cells, neutrophils, and macrophages
all appeared to either directly or indirectly affect the levels of
various factors (Figure S3A). Our data suggested that no single
cell type was entirely responsible for the increase in any given
cytokine or chemokine but, likely, that a complex interdependent
network of cells was involved. We focused on the neutrophil-
related factors MIP-2 and G-CSF as well as the inflammatory
factor IL-6, which was the most elevated inflammatory cytokine.
In the case of MIP-2, depletion of NK cells, macrophages, or
neutrophils led to a sharp decrease in the intratumoral concen-
tration of this chemokine (Figure 4C), whereasG-CSF production
seemed to be dependent on the presence of NK cells and mac-
rophages (Figure 4D). Finally, IL-6 appeared to be dependent on
the presence of all interrogated effector cells to various degrees
(Figure 4E).
Although MIP-2 can be produced by macrophages (Wolpe
et al., 1989) and neutrophils can also release MIP-2 (as well as
IL-6) from pre-formed granules (Lacy and Stow, 2011), it was
Figure 3. Fc/IL-2+TA99 Induces Immune
Infiltrates within B16F10 Tumors
(A) Representative immunofluorescence of im-
mune cell infiltrates into B16F10 tumors treated
with PBS or Fc/IL-2+TA99. Blue, Hoechst 33342;
red, indicated lineage marker. Magnification, 203.
Scale bar, 100 mm.
(B) Analysis of immune cell infiltrates into treated
B16F10 tumors, normalized to total tumor mass,
with lineage markers as indicated. n = 10/group.
*p < 0.05, **p < 0.01 between the indicated groups.
(C) Tumor growth and survival curves of C57BL/6
mice bearing subcutaneous B16F10 tumors
treated with PBS and Fc/IL-2+TA99 and with
depletions as indicated. n = 10/group. *p < 0.05,
**p < 0.01 versus the corresponding color group in
the legend.
Data are mean ± SEM. See also Figure S2.interesting to note that depletion of NK cells also reduced intra-
tumoral MIP-2 levels (Figure 4C). NK cells are not known to
generate MIP-2, and, indeed, sorted intratumoral CD3NK1.1+
NK cells showed little expression ofCxcl2 asmeasured by quan-
titative PCR (qPCR) (Figure S3B). We hypothesized that NK cells
may be modulating the production of MIP-2 by macrophages.
When Cxcl2 expression in intratumoral CD11b+F4/80+ macro-
phages was quantified, we observed a significant upregulation
of the genewhen treating with Fc/IL-2+TA99 (Figure 4F). Further-
more, with NK cell depletion, we observed a significant downre-
gulation of Cxcl2 expression in these macrophages (Figure 4F),
suggesting that NK cells influence macrophage production of
MIP-2, but solely upon Fc/IL-2+TA99 treatment.
Infiltration and Function of Neutrophils and Contribution
of Respiratory Burst
A striking aspect of the synergy of Fc/IL-2+TA99 was the in-
crease in neutrophil population above all other treatment condi-Cancer Cell 27, 489–5tions (Figure 3B). We further explored the
causes of this pronounced infiltration by
depleting different cell types or neutral-
izing different factors that may be
involved in boosting neutrophil infiltration
or function. Both CD8+ T cell and NK cell
depletion resulted in a statistically sig-
nificant drop of intratumoral neutrophils
(Figure 5A). Because NK cells modulated
intratumoral MIP-2 levels via macro-
phages (Figures 4C and 4F), it follows
that the absence of NK cells may impair
neutrophil infiltration. Moreover, both
CD8+ T cells and NK cells contributed
to intratumoral interferon g (IFNg) (Fig-
ure S3A), which has been shown to play
a role in neutrophil longevity (Pelletier
et al., 2010). Indeed, intratumoral neu-
trophils also decreased when IFNg was
neutralized (Figure 5A).
We proceeded to investigate other
potential factors promoting neutrophilinfiltration. C5a of the complement system is known to be a
neutrophil chemoattractant (Guo andWard, 2005), and depletion
of complement via cobra venom factor (CVF) did decrease intra-
tumoral neutrophils (Figure 5A). Antibody-mediated neutraliza-
tion of MIP-2 also led to a decrease in intratumoral neutrophils
(Figure 5A), suggesting that both of these neutrophil chemoat-
tractants play a role in neutrophil infiltration into the tumor.
Furthermore, blockade of either factor during Fc/IL-2+TA99
treatment resulted in a significant reduction in treatment efficacy
(Figure 5B).
Functionally, we found that intratumoral neutrophils appear
to be releasing cytosolic vesicles and granules, given the
high surface expression of CD63 and CD11b (Kuijpers et al.,
1991) compared with neutrophils in the peripheral blood
(Figure 5C). Moreover, the activation state of the neutrophils
was affected by IFNg, as observed by surface expression of
CD16. Although neutrophil surface expression of CD32 re-
mains unchanged under activating conditions, CD16 surface01, April 13, 2015 ª2015 Elsevier Inc. 493
Figure 4. Fc/IL-2+TA99 Induces an Intratu-
moral Cytokine Storm and Uniquely In-
creases Several Inflammatory and Neutro-
phil-Related Factors
(A and B) Luminex analysis of intratumoral con-
centrations of a panel of cytokines and chemo-
kines in tumors treated with (A) PBS or Fc/IL-
2+TA99 and (B) Fc/IL-2 or Fc/IL-2+TA99. Blue bars
indicate factors elevated only in Fc/IL-2+TA99-
treated tumors. *p < 0.05, **p < 0.01 versus Fc/IL-
2+TA99.
(C–E) Intratumoral concentrations of (C) MIP-2, (D)
G-CSF, and (E) IL-6 in tumors treated with Fc/IL-
2+TA99 and with depletions as indicated. n = 10/
group.
(F) Cxcl2 expression in CD11b+F4/80+ macro-
phages sorted from tumors treated with the indi-
cated conditions, normalized to b-2 microglobulin
(B2m) expression. n = 5/group.
*p < 0.05, **p < 0.01, ***p < 0.001 between the
indicated groups. Data are mean ± SEM. See also
Figure S3.expression is reduced drastically (Huizinga et al., 1988;
Kuijpers et al., 1991). This effect is observed with Fc/IL-
2+TA99 because intratumoral neutrophils showed decreased
surface CD16/32 compared with peripheral blood neutrophils,
but neutralization of IFNg partially reversed this trend (Fig-
ure 5C). Another effector function of neutrophils is the produc-
tion of reactive nitrogen species via inducible nitric oxide
synthase (iNOS) (Fang, 2004). We found that only Fc/IL-
2+TA99 treatment led to an increase in iNOS, but those levels
were reduced when either neutrophils were depleted or IFNg
was neutralized, suggesting that neutrophils may be a poten-
tial, but not necessarily exclusive, source of iNOS and that
IFNg is important for the induction of iNOS (Figure S4A).
Furthermore, iNOS transcription was nearly undetectable in
neutrophils from peripheral blood but was increased signifi-
cantly in intratumoral neutrophils (Figure S4B). Overall, it ap-
pears that Fc/IL-2+TA99 led to the infiltration and activation
of neutrophils, releasing factors that contribute to inflammation
and tumor killing.494 Cancer Cell 27, 489–501, April 13, 2015 ª2015 Elsevier Inc.Another well known cytotoxic function
of neutrophils is the generation of reactive
species through respiratory burst (Fang,
2004), and we hypothesized that neutro-
phils might contribute to tumor killing via
respiratory burst, whose activity can be
quantified from the in vivo injection of lu-
minol (Gross et al., 2009). Surprisingly,
both Fc/IL-2- and Fc/IL-2+TA99-treated
mice exhibited an increased luminescent
signal over the initial background mea-
surement (Figure 5D). Although the respi-
ratory burst activity appeared to also be
a result of synergy, because depletion
of CD8+ T cells or neutralization of IFNg
resulted in a decrease in luminol-
derived chemiluminescence (Figure 5E),
it seemed unlikely that the source of therespiratory burst was from neutrophils because Fc/IL-2 alone
did not result in increased neutrophil infiltration (Figure 3B).
This was confirmed upon neutrophil depletion because the
chemiluminescence signal was essentially unchanged (Fig-
ure S4F). Instead, we identified eosinophils as a likely source
of this respiratory burst, given an increase in intratumoral IL-5
and CD11b+Siglec-F+ eosinophils with both Fc/IL-2 and Fc/
IL-2+TA99 (Figures S4C and S4D). Moreover, depletion of
eosinophils via anti-IL-5 antibody reduced luminol-derived
chemiluminescence and diminished the therapeutic efficacy of
Fc/IL-2+TA99 (Figures S4E–S4G). Given the apparent impor-
tance of the respiratory burst, we proceeded to investigate its
contribution to the efficacy of Fc/IL-2+TA99 regardless of the
cellular source. We employed p47phox knockout (KO) mice,
which lack the p47phox subunit necessary for NADPH oxidase
(Jackson et al., 1995), leading to a lack of luminol-derived chem-
iluminescence (Figure S4H). Indeed, the efficacy of the therapy
was reduced in the treatment of these mice (Figure 5F), empha-
sizing the importance of respiratory burst in tumor control.
Figure 5. Neutrophil Infiltration and Func-
tion Modulated by a Suite of Immunological
Elements; Oxidative Burst Contributes to
Therapeutic Efficacy
(A) Analysis of CD11b+Ly-6C+Ly-6G+ neutrophil
infiltration into B16F10 tumors treated with PBS
and Fc/IL-2+TA99 and with depletions/neutraliza-
tions as indicated, normalized to total tumor mass.
Complement was depleted by CVF. n = 10/group.
*p < 0.05, **p < 0.01, ***p < 0.001 versus Fc/IL-
2+TA99.
(B) Tumor growth and survival curves of C57BL/6
mice bearing subcutaneous B16F10 tumors
treated with PBS and Fc/IL-2+TA99 and with de-
pletions/neutralizations as indicated. n = 5/group.
*p < 0.05, **p < 0.01 versus Fc/IL-2+TA99.
(C) Analysis of degranulation and activation
markers of neutrophils in mice treated with Fc/
IL-2+TA99. n = 5/group. *p < 0.05, ***p < 0.001
between the indicated groups.
(D and E) B16F10 tumors were treated with the
indicated treatments and depletions/neutraliza-
tions as applicable. On days of imaging, luminol
was injected, and average radiant luminescence
was quantified. Representative images on day 8
are shown. In (D): (a) PBS, (b) Fc/IL-2, (c) TA99, (d)
Fc/IL-2+TA99. In (E): (a) PBS, (b) Fc/IL-2+TA99, (c)
Fc/IL-2+TA99+anti-CD8a, (d) Fc/IL-2+TA99+anti-
IFNg. Arrows indicate points of treatment. n = 5/
group. *p < 0.05, **p < 0.01, ***p < 0.001, ****p <
0.0001 Fc/IL-2+TA99 versus the corresponding
color group in the legend. Scale bar, 1 cm.
(F) Tumor growth and survival curves of C57BL/6
mice or p47phox KO mice bearing subcutaneous
B16F10 tumors treated with PBS or Fc/IL-2+TA99.
n = 5/group. *p < 0.05, **p < 0.01 versus p47phox
KO: Fc/IL-2+TA99.
Data are mean ± SEM. See also Figure S4.Fc/IL-2 Promotes NKCell andCD8+ TCell Activation and
Cytotoxic Function
Although NK cells and CD8+ T cells potentiated neutrophil infil-
tration and function, these cells themselves were likely contrib-
uting directly to therapeutic efficacy. Because Fc/IL-2 or Fc/IL-
2+TA99 significantly increased intratumoral NK cells and CD8+
T cells, we proceeded to investigate how Fc/IL-2 in either case
may affect their effector functions. Fc/IL-2 significantly activated
intratumoral NK cells, as measured through the activation
marker KLRG-1 (Huntington et al., 2007; Figure 6A). Fc/IL-2
also activated intratumoral CD8+ T cells, as measured through
the activation markers CD25, CD69, and CD71 (Neckers and
Cossman, 1983; Schwartz, 2003), with CD25 and CD69 being
highly significant (Figure 6B and 6C), although CD71 showed a
weaker trend (Figure S5A). The immune checkpoint receptors
PD-1 and CTLA-4 are also markers for T cell activation (Keir
et al., 2008; Walunas et al., 1994), but no differences were
identified 3 days after treatment (Figure S5B and S5C). There-
fore, although Fc/IL-2 alone led to significantly increased CD8+
T cell infiltration and activation in the tumor, it was apparent
that T cells alone were insufficient to account for the strong
tumor growth inhibition caused by Fc/IL-2+TA99 (Figure 1C).
We next wanted to investigate the cytotoxic function of
NK cells and CD8+ T cells. With Fc/IL-2 or Fc/IL-2+TA99, NKcells appeared to secrete IFNg and degranulate, as measured
through CD107a (Betts et al., 2003), although, surprisingly,
both treatment conditions were comparable (Figures 6D and
6E), suggesting that the presence of an anti-tumor antibody
in vivo does not directly affect these particular functions
assayed 2 days after treatment. A similar observation was
made for CD8+ T cells (Figures 6F and 6G), although infiltrating
CD8+ T cells did exhibit reactivity against B16F10, as
demonstrated by enzyme-linked immunospot (ELISPOT)
(Figure S5D).
Given that CD8+ T cells produced IFNg during anti-tumor
responses, it was of interest to determine the contribution of
IFNg in controlling tumor growth. Administration of anti-IFNg
antibody demonstrated an intermediate reduction in therapeutic
efficacy (Figure 6H). The previously observed increase in intra-
tumoral tumor necrosis factor a (TNF-a) (Figure 4A) could
potentially be generated by infiltrating CD8+ T cells as well, but
neutralization of this cytokine did not appear to reduce the
efficacy of the therapy (Figure S5E). It has also been shown
that IFNg upregulates MHC-I expression on B16F10 (Ju et al.,
2005). Similarly, in our system, we confirmed, via immunohisto-
chemistry, that an IFNg-dependent increase of MHC-I expres-
sion on B16F10 occurred when tumors were treated with Fc/
IL-2+TA99 (Figure S5F).Cancer Cell 27, 489–501, April 13, 2015 ª2015 Elsevier Inc. 495
Figure 6. Fc/IL-2 and Fc/IL-2+TA99 Have a
Comparable Effect on NK Cells and CD8+
T cells
(A–C) Analysis of NK cell or CD8+ T cell activation
markers as a percentage of the intratumoral
NK cell or CD8+ T cell population, respectively.
The following conditions were investigated: (A)
CD3NK1.1+KLRG1+ cells, (B) CD3+CD8+CD25+
cells, (C) CD3+CD8+CD69+ cells.
(D–G) Analysis of IFNg-producing or degranulating
NK cells or CD8+ T cells as a percentage of the
intratumoral NK cell or CD8+ T cell population,
respectively. The following conditions were
investigated: (D) CD3NK1.1+IFNg+ cells, (E)
CD3NK1.1+CD107a+ cells, (F) CD3+CD8+IFNg+
cells, (G) CD3+CD8+CD107a+ cells. n = 10/group.
*p < 0.05, **p < 0.01, ***p < 0.001 between the
indicated groups.
(H) Tumor growth and survival curves of C57BL/6
mice bearing subcutaneous B16F10 tumors
treated with PBS, Fc/IL-2+TA99, or Fc/IL-2+TA99
with anti-IFNg antibody. n = 5/group. *p < 0.05
versus Fc/IL-2+TA99.
Data are mean ± SEM. See also Figure S5.Adoptive Cell Transfer of pmel-1 Combined with Fc/IL-
2+TA99 Confers Robust Cures and Expansion of the
pmel-1 Population
Given the importance of CD8+ T cells in Fc/IL-2+TA99 therapy
and the rarity of durable cures following cessation of treatment,
we testedwhether increasing the number of tumor specific CD8+
T cells would be sufficient to generate complete cures. To
accomplish this, tumor-bearingmice received an adoptive trans-
fer of 107 pmel-1 CD8+ T cells and were treated with Fc/IL-2 and/
or TA99 as described previously. Although irradiated mice
treated with Fc/IL-2+TA99 or pmel-1+TA99 showed only a slight
initial delay in tumor growth, mice treated with pmel-1+Fc/IL-2
showed a significant survival advantage, but all tumors eventu-
ally grew out (Figure 7A). However, all five mice treated with
the triple combination of pmel-1+Fc/IL-2+TA99 experienced
complete regression of their tumors, with four of five continuing
to survive up to 150 days (Figure 7A). Moreover, these mice
developed prominent vitiligo, suggesting that a strong melano-
cyte-specific T cell response was generated (Figure 7B).
To further understand the activity of the pmel-1 CD8+ T cells
when combined with Fc/IL-2 and/or TA99, the experiment was
repeatedwith pmel-1CD8+ T cells expressing luciferase, allowing
us tomonitor thispopulationbybioluminescence.Without anyFc/
IL-2, the signal was very weak, suggesting that the adoptively
transferred T cell population did not expand in vivo (Figure 7C).
Conversely, any treatment with Fc/IL-2 resulted in cumulatively
increasing luminescence (Figure 7C). In these cases, the pmel-1
CD8+ T cells appeared to survive and expand within these mice,496 Cancer Cell 27, 489–501, April 13, 2015 ª2015 Elsevier Inc.with a luciferase signal observed up to
140 days after the initial adoptive transfer
(FigureS6A). To test thememory response
of the mice cured by pmel-1+Fc/IL-
2+TA99, 105 B16F10 cells were injected
subcutaneously into the opposite flank,
and no palpable tumors were formed forup to 30 days after rechallenge (data not shown). The capability
of Fc/IL-2 treatment to sustain the survival of adoptively trans-
ferred T cells was consistent with the increased infiltration and
activation of endogenous T cells by such treatments (Figures 3B
and 6B and 6C). Also analogous is the insufficiency of this T cell
effect to produce long-term efficacy in the absence of TA99
antibody treatment. It is clear that even a huge population of
melanocyte-specific CD8+ T cells sustained by Fc/IL-2 alone
was insufficient to induce durable cures without the necessary
contribution of an anti-tumor antigen antibody. In this case, how-
ever, neutrophils appeared to be dispensable when the third
component of pmel-1 CD8+ T cells was introduced (Figure S6B).
DISCUSSION
There have been determined clinical attempts to combine anti-
tumor antigen antibodies with pulsed IL-2 treatment in phase I
(Bajorin et al., 1990; Bleumer et al., 2006; Eisenbeis et al.,
2004; Fleming et al., 2002; Repka et al., 2003) and phase II
(Khan et al., 2006; Mani et al., 2009; Poire´ et al., 2010) clinical tri-
als, all without evidence of efficacy. PEGylated IL-2 with an
increased serum half-life has also been tested clinically as a
monotherapy and was found not to be clinically superior (Yang
et al., 1995). This suggests that a critical aspect missing may
bemore persistent IL-2 signaling, and, in fact, the clinical admin-
istration of anti-GD2 antibody, continuous infusion of IL-2, sub-
cutaneous GM-CSF, and isotretinoin led to increased survival
in children with high-risk neuroblastoma (Yu et al., 2010). Indeed,
Figure 7. Pmel-1+Fc/IL-2+TA99 Induces Long-Term Control of B16F10 Growth through Activation and Expansion of pmel-1 Cells
(A) Tumor growth and survival curves of C57BL/6 mice bearing subcutaneous B16F10 tumors and treated with the indicated combinations of Fc/IL-2, TA99, and
107 CD8+ pmel-1 T cells. All mice received total body irradiation 5 days after tumor inoculation. n = 3–5/group. **p < 0.01 versus pmel-1+Fc/IL-2+TA99.
(B) Representative pictures 100 days after tumor inoculation showing vitiligo after treatment. (a) Non-treated, non-tumor-bearing, and age-matched. (b) pmel-
1+Fc/IL-2+TA99-treated.
(C) Experimentally identical to (A), except CD8+ T cells were derived from luciferase-expressing pmel-1 mice. On days of imaging, D-luciferin was injected,
and average radiant luminescence was quantified. Representative pictures on day 14 are shown: (a) pmel-1, (b) pmel-1+Fc/IL-2, (c) pmel-1+TA99, (d) pmel-1+Fc/
IL-2+TA99. Arrows indicate point of treatment. n = 5/group. *p < 0.05, ****p < 0.0001 pmel-1 versus the corresponding color group in the legend. #p < 0.05,
####p < 0.0001 pmel-1+TA99 versus the corresponding color group in the legend. Scale bar, 1 cm.
Data are mean ± SEM. See also Figure S6.our own combination of an anti-tumor antigen antibody and a
fusion protein bestowing prolonged IL-2 signaling, despite its
greater simplicity, demonstrated significant efficacy in various
syngeneic murine tumor models.
The demonstrated key components of the immune response
induced by our combination immunotherapy are summarized
in Figure 8. We find that our model reflects many observations
of critical interactions between various effectors during adminis-
tration of cancer immunotherapy reported in the literature. In
syngeneic tumor models, the efficacy of antibody treatments
has been shown previously to be dependent on and synergize
with CD8+ T cell activity (Abe`s et al., 2010; Park et al., 2010;
Stagg et al., 2011). Stimulation of CD8+ T cells provides not
only the benefit of direct tumor killing but also the modulation
of polymorphonuclear leukocytes (PMNs) for ADCC, such as
through the release of cytokines like IFNg, known to promote
neutrophil activity (Pelletier et al., 2010). Although a concern
with IL-2 administration could be the expansion of the intratu-
moral Treg cell population, we find that this does not dramaticallyaffect the efficacy of our therapy. Indeed, despite the unchanged
CD8/Treg cell ratio (Figure S2D), the enhanced response by the
innate immune system via the anti-tumor antigen antibody may
aid in overcoming immunosuppression by Treg cells. However,
increased Treg cell numbers may limit robust overall cures from
this two-agent system.
A significant interaction between neutrophils and other
effector cells in our own system was evident, because infiltration
and activation of neutrophils was dependent on IFNg and, by as-
sociation, the cells that produce it. The production of the neutro-
phil chemoattractant MIP-2 (Wolpe et al., 1989) bymacrophages
has also been shown to be important for efficacy, despite reports
that associate the human homolog IL-8 with increased cancer
progression (Waugh and Wilson, 2008), potentially through the
recruitment of N2-polarized neutrophils by Treg cells or the tu-
mors themselves (Fridlender and Albelda, 2012). However, in
our system, it appears that the combination of Fc/IL-2+TA99 in-
duces MIP-2 release by macrophages for the purpose of recruit-
ing neutrophils, which were clearly anti-tumor in this context. InCancer Cell 27, 489–501, April 13, 2015 ª2015 Elsevier Inc. 497
Figure 8. Mechanistic Model of the Immune Response Induced by
Fc/IL-2+TA99 against B16F10
The combination of Fc/IL-2 and anti-tumor IgG administration induces a
synergistic innate and adaptive immune response. Fc/IL-2 increases the
sustained exposure of NK cells and CD8+ T cells to IL-2 signaling, activating
them. The presence of three factors—anti-tumor antibodies, Fc/IL-2, and
NK cells—induces macrophages to release the neutrophil chemoattractant
MIP-2. This chemokine recruits neutrophils that, expressing FcgR, likely
engage the tumor via the opsonizing antibodies and perform ADCC. These and
other PMNs have their cytotoxic function bolstered by IFNg released by the
activated NK cells and CD8+ T cells. Finally, NK cells and CD8+ T cells perform
a direct effector function against the tumor cells as well. Overall, this complex
network of immune responses results in controlled B16F10 growth during the
course of treatment.addition, many other cytokines in the intratumoral cytokine storm
induced by Fc/IL-2+TA99 are known to enhance neutrophil
activity, such as TNF-a and GM-CSF (Pelletier et al., 2010) or
IL-1b and G-CSF (Colotta et al., 1992).
Interestingly, IL-6 was highly elevated as well, and, in many
cases, tumor-derived IL-6 has been associated with increased
disease progression (Allavena et al., 2000; Balkwill et al., 2005;
Pollard, 2004). Nevertheless, IL-6 is a pleiotropic cytokine critical
for transitioning from the innate to the adaptive response
because it promotes CD3+ T cell trafficking and survival (Jones,
2005). In our immunotherapy, we observed IL-6 derivation
from various effector cells, including neutrophils, which suggest
that, in addition to tumor killing, neutrophils may also function to
modulate the intratumoral T cell response. Overall, there are
many indications that, through the administration of these two
agents simultaneously, the tumor microenvironment may un-
dergo a repolarization so that, with the presence of many inflam-
matory and pleiotropic cytokines and chemokines, the observed
response elicited from the immune system becomes one that is
anti-tumoral.
To date, little focus has been placed on eliciting strong neutro-
phil responses against tumors. Tumor-associated neutrophils498 Cancer Cell 27, 489–501, April 13, 2015 ª2015 Elsevier Inc.are often considered as pro-tumor ‘‘N2’’ polarized neutrophils
(Fridlender and Albelda, 2012), and the immunosuppressive
granulocytic subtype of myeloid derived suppressor cells also
possess a similar phenotype (Gabrilovich et al., 2012). However,
there are examples where neutrophils are required for antibody
therapeutic effects in xenograft tumor control studies (Eisenbeis
et al., 2003; Schneider-Merck et al., 2010; Siders et al., 2010). In
fact, it seems intuitive to utilize the underappreciated neutrophil
to mount an anti-tumor response, given that they are the most
abundant of circulating leukocytes, and, in other forms of im-
mune challenge, neutrophils are the first responders, inducing
massive cell killing. Moreover, neutrophils have been shown to
release chemotactic factors to recruit other effector cells (Lillard
et al., 1999) and produce cytokines that can modulate T cells
(Cassatella, 1995). Although a robust T cell response is ultimately
required for tumor rejection and immunological memory, the
innate arm of the immune system may provide the necessary
support to boost existing T cell-focused immunotherapies. This
was demonstrated when we combined the existing Fc/IL-
2+TA99 with adoptive T cell transfer.
Wesurmisedandconfirmed that creatinganoverwhelmingme-
lanocyte-specific CD8+ T cell response via adoptive cell transfer
provided the sustained effector function necessary for complete
cures in combination with Fc/IL-2+TA99. Although Fc/IL-2 treat-
ment alone maintained the survival of adoptively transferred
pmel-1 cells, it is significant that, in the absence of the antibody
to bridge tumors to innate effectors, all pmel-1+Fc/IL-2-treated
mice ultimately succumbed to the tumor. Therefore, in this sys-
tem, antibody-mediated effects remained critical for providing tu-
mor killing that contributed to long-term T cell-mediated efficacy.
In this study, we uncovered a mechanism of tumor control
induced by Fc/IL-2+TA99 that differs qualitatively from a pre-
dominant importance of NK cells, a view that has previously
been held for combination treatments using anti-tumor anti-
bodies and IL-2. Inparticular, thepotential for a strong synergistic
interaction of T cells and neutrophils has been noted in infectious
and autoimmune diseases (Mu¨ller et al., 2009) but has been
largely unappreciated as a contributor to tumor immunotherapy
(Buonocore et al., 2008). Therefore, although work in the immu-
notherapy space has traditionally been focused on boosting
only an anti-tumor T cell or NK cell response, a more powerful
approach may be to identify ways to conscript neutrophils and
other innate effector cells to synergize with existing immuno-
therapies that stimulate T cell activity.
EXPERIMENTAL PROCEDURES
More detailed procedures can be found in the Supplemental Experimental
Procedures.
Mice
C57BL/6NTac mice (Taconic), C3H/HeNTac mice (Taconic), and pmel-1
(B6.Cg-Thy1a/Cy Tg(TcraTcrb8)Rest/J) mice (The Jackson Laboratory) were
aged between 6–10 weeks before tumor induction. All animal work was con-
ducted under the approval of the Massachusetts Institute of Technology
(MIT) Division of Comparative Medicine in accordance with federal, state,
and local guidelines.
Tumor Inoculation and Treatment
For induction of B16F10 tumors, 106 cells in 100 ml of PBS were injected sub-
cutaneously into the flanks of C57BL/6 mice. Retro-orbital injection of PBS,
IL-2 (6 mg, PeproTech), Fc/IL-2 (25 mg), MSA/IL-2 (30 mg), and/or TA99 (100 mg)
was done on days 6, 12, 18, 24, and 30 after tumor inoculation for a total of five
treatments. Additional details, models, depletions, neutralizations, and adop-
tive cell transfer are described in the Supplemental Experimental Procedures.
Flow Cytometry
Tumor inoculation and treatment were done as described previously. Single-
cell suspensions were prepared, stained, and analyzed as described in the
Supplemental Experimental Procedures.
Intratumoral Cytokine Analysis
Tumor inoculation and treatment were done as described previously. Tumors
were homogenized, and protein concentrations were normalized and evalu-
ated in triplicate using the Mouse 32-Plex cytokine/chemokine panel luminex
assay as performed by Eve Technologies. More detailed information can be
found in the Supplemental Experimental Procedures.
Statistics
Statistical analysis was performed with GraphPad Prism 5 software
(GraphPad). More detailed information can be found in the Supplemental
Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.ccell.2015.03.004.
AUTHOR CONTRIBUTIONS
E.F.Z., S.A.G., and C.F.O. designed and performed experiments. B.H.K., R.S.,
M.J.K., K.D.M., A.A., and R.T.W. performed experiments. M.C.M. provided
analysis of histology. M.T.S., J.S.K., M.B.Y., D.J.I., L.M.W., and G.D. provided
critical reagents and advice. E.F.Z., S.A.G, C.F.O., and K.D.W. interpreted data
and wrote the manuscript.
ACKNOWLEDGMENTS
We thank Dr. Bronson for pathological analysis and the staff of the Swanson
Biotechnology Center at the Koch Institute for technical assistance. This study
was supported by National Cancer Institute Grant NCI CA174795. E.F.Z. was
supported by the NIH/NIGMS Biotechnology Training Program. S.A.G. and
C.F.O were supported by a NSF graduate research fellowship.
Received: November 21, 2013
Revised: October 19, 2014
Accepted: March 9, 2015
Published: April 13, 2015
REFERENCES
Abe`s, R., Ge´lize´, E., Fridman, W.H., and Teillaud, J.-L. (2010). Long-lasting
antitumor protection by anti-CD20 antibody through cellular immune
response. Blood 116, 926–934.
Allavena, P., Sica, A., Vecchi, A., Locati, M., Sozzani, S., and Mantovani, A.
(2000). The chemokine receptor switch paradigm and dendritic cell migration:
its significance in tumor tissues. Immunol. Rev. 177, 141–149.
Anderson, C.L., Chaudhury, C., Kim, J., Bronson, C.L., Wani, M.A., and
Mohanty, S. (2006). Perspective— FcRn transports albumin: relevance to
immunology and medicine. Trends Immunol. 27, 343–348.
Bajorin, D.F., Chapman, P.B., Wong, G., Coit, D.G., Kunicka, J., Dimaggio, J.,
Cordon-Cardo, C., Urmacher, C., Dantes, L., Templeton, M.A., et al. (1990).
Phase I evaluation of a combination of monoclonal antibody R24 and inter-
leukin 2 in patients with metastatic melanoma. Cancer Res. 50, 7490–7495.
Baley, P.A., Yoshida, K., Qian, W., Sehgal, I., and Thompson, T.C. (1995).
Progression to androgen insensitivity in a novel in vitro mouse model for pros-
tate cancer. J. Steroid Biochem. Mol. Biol. 52, 403–413.Balkwill, F., Charles, K.A., and Mantovani, A. (2005). Smoldering and polarized
inflammation in the initiation and promotion of malignant disease. Cancer Cell
7, 211–217.
Baudino, L., Shinohara, Y., Nimmerjahn, F., Furukawa, J., Nakata, M.,
Martı´nez-Soria, E., Petry, F., Ravetch, J.V., Nishimura, S., and Izui, S. (2008).
Crucial role of aspartic acid at position 265 in the CH2 domain for murine
IgG2a and IgG2b Fc-associated effector functions. J. Immunol. 181, 6664–
6669.
Betts, M.R., Brenchley, J.M., Price, D.A., De Rosa, S.C., Douek, D.C.,
Roederer, M., and Koup, R.A. (2003). Sensitive and viable identification of
antigen-specific CD8+ T cells by a flow cytometric assay for degranulation.
J. Immunol. Methods 281, 65–78.
Bleumer, I., Oosterwijk, E., Oosterwijk-Wakka, J.C., Vo¨ller, M.C., Melchior, S.,
Warnaar, S.O., Mala, C., Beck, J., and Mulders, P.F.A. (2006). A clinical trial
with chimeric monoclonal antibody WX-G250 and low dose interleukin-2
pulsing scheme for advanced renal cell carcinoma. J. Urol. 175, 57–62.
Buonocore, S., Haddou, N.O., Moore, F., Florquin, S., Paulart, F., Heirman, C.,
Thielemans, K., Goldman, M., and Flamand, V. (2008). Neutrophil-dependent
tumor rejection and priming of tumoricidal CD8+ T cell response induced by
dendritic cells overexpressing CD95L. J. Leukoc. Biol. 84, 713–720.
Carson, W.E., Parihar, R., Lindemann, M.J., Personeni, N., Dierksheide, J.,
Meropol, N.J., Baselga, J., and Caligiuri, M.A. (2001). Interleukin-2 enhances
the natural killer cell response to Herceptin-coated Her2/neu-positive breast
cancer cells. Eur. J. Immunol. 31, 3016–3025.
Cassatella, M.A. (1995). The production of cytokines by polymorphonuclear
neutrophils. Immunol. Today 16, 21–26.
Clemente, C.G., Mihm, M.C., Jr., Bufalino, R., Zurrida, S., Collini, P., and
Cascinelli, N. (1996). Prognostic value of tumor infiltrating lymphocytes
in the vertical growth phase of primary cutaneous melanoma. Cancer 77,
1303–1310.
Clynes, R.A., Towers, T.L., Presta, L.G., and Ravetch, J.V. (2000). Inhibitory Fc
receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6,
443–446.
Colotta, F., Re, F., Polentarutti, N., Sozzani, S., and Mantovani, A. (1992).
Modulation of granulocyte survival and programmed cell death by cytokines
and bacterial products. Blood 80, 2012–2020.
Dyall, R., Vasovic, L.V., Clynes, R.A., and Nikolic-Zugic, J. (1999). Cellular
requirements for the monoclonal antibody-mediated eradication of an estab-
lished solid tumor. Eur. J. Immunol. 29, 30–37.
Eisenbeis, C.F., Caligiuri, M.A., and Byrd, J.C. (2003). Rituximab: converging
mechanisms of action in non-Hodgkin’s lymphoma? Clin. Cancer Res. 9,
5810–5812.
Eisenbeis, C.F., Grainger, A., Fischer, B., Baiocchi, R.A., Carrodeguas, L.,
Roychowdhury, S., Chen, L., Banks, A.L., Davis, T., Young, D., et al. (2004).
Combination immunotherapy of B-cell non-Hodgkin’s lymphoma with rituxi-
mab and interleukin-2: a preclinical and phase I study. Clin. Cancer Res. 10,
6101–6110.
Fang, F.C. (2004). Antimicrobial reactive oxygen and nitrogen species: con-
cepts and controversies. Nat. Rev. Microbiol. 2, 820–832.
Feau, S., Arens, R., Togher, S., and Schoenberger, S.P. (2011). Autocrine IL-2
is required for secondary population expansion of CD8(+) memory T cells. Nat.
Immunol. 12, 908–913.
Ferris, R.L., Jaffee, E.M., and Ferrone, S. (2010). Tumor antigen-targeted,
monoclonal antibody-based immunotherapy: clinical response, cellular immu-
nity, and immunoescape. J. Clin. Oncol. 28, 4390–4399.
Fleming, G.F., Meropol, N.J., Rosner, G.L., Hollis, D.R., Carson, W.E., 3rd,
Caligiuri, M., Mortimer, J., Tkaczuk, K., Parihar, R., Schilsky, R.L., and
Ratain, M.J. (2002). A phase I trial of escalating doses of trastuzumab com-
bined with daily subcutaneous interleukin 2: report of cancer and leukemia
group B 9661. Clin. Cancer Res. 8, 3718–3727.
Fridlender, Z.G., and Albelda, S.M. (2012). Tumor-associated neutrophils:
friend or foe? Carcinogenesis 33, 949–955.
Gabrilovich, D.I., Ostrand-Rosenberg, S., and Bronte, V. (2012). Coordinated
regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253–268.Cancer Cell 27, 489–501, April 13, 2015 ª2015 Elsevier Inc. 499
Gross, S., Gammon, S.T., Moss, B.L., Rauch, D., Harding, J., Heinecke, J.W.,
Ratner, L., and Piwnica-Worms, D. (2009). Bioluminescence imaging of mye-
loperoxidase activity in vivo. Nat. Med. 15, 455–461.
Guo, R.-F., and Ward, P.A. (2005). Role of C5a in inflammatory responses.
Annu. Rev. Immunol. 23, 821–852.
Huizinga, T.W.J., van der Schoot, C.E., Jost, C., Klaassen, R., Kleijer, M., von
dem Borne, A.E.G.K., Roos, D., and Tetteroo, P.A.T. (1988). The PI-linked re-
ceptor FcRIII is released on stimulation of neutrophils. Nature 333, 667–669.
Huntington, N.D., Tabarias, H., Fairfax, K., Brady, J., Hayakawa, Y., Degli-
Esposti, M.A., Smyth, M.J., Tarlinton, D.M., and Nutt, S.L. (2007). NK cell
maturation and peripheral homeostasis is associated with KLRG1 up-regula-
tion. J. Immunol. 178, 4764–4770.
Jackson, S.H., Gallin, J.I., and Holland, S.M. (1995). The p47phox mouse
knock-out model of chronic granulomatous disease. J. Exp. Med. 182,
751–758.
Jones, S.A. (2005). Directing transition from innate to acquired immunity:
defining a role for IL-6. J. Immunol. 175, 3463–3468.
Ju, S.-A., Lee, S.-C., Kwon, T.-H., Heo, S.-K., Park, S.-M., Paek, H.-N., Suh,
J.-H., Cho, H.R., Kwon, B., Kwon, B.S., and Kim, B.S. (2005). Immunity to mel-
anoma mediated by 4-1BB is associated with enhanced activity of tumour-
infiltrating lymphocytes. Immunol. Cell Biol. 83, 344–351.
June, C.H. (2007). Principles of adoptive T cell cancer therapy. J. Clin. Invest.
117, 1204–1212.
Kalia, V., Sarkar, S., Subramaniam, S., Haining, W.N., Smith, K.A., and Ahmed,
R. (2010). Prolonged interleukin-2Ralpha expression on virus-specific CD8+
T cells favors terminal-effector differentiation in vivo. Immunity 32, 91–103.
Keir, M.E., Butte, M.J., Freeman, G.J., and Sharpe, A.H. (2008). PD-1 and its
ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677–704.
Khan, K.D., Emmanouilides, C., Benson, D.M., Jr., Hurst, D., Garcia, P.,
Michelson, G., Milan, S., Ferketich, A.K., Piro, L., Leonard, J.P., et al. (2006).
A phase 2 study of rituximab in combination with recombinant interleukin-2
for rituximab-refractory indolent non-Hodgkin’s lymphoma. Clin. Cancer
Res. 12, 7046–7053.
Konrad, M.W., Hemstreet, G., Hersh, E.M., Mansell, P.W.A., Mertelsmann, R.,
Kolitz, J.E., and Bradley, E.C. (1990). Pharmacokinetics of recombinant inter-
leukin 2 in humans. Cancer Res. 50, 2009–2017.
Kuijpers, T.W., Tool, A.T., van der Schoot, C.E., Ginsel, L.A., Onderwater, J.J.,
Roos, D., and Verhoeven, A.J. (1991). Membrane surface antigen expression
on neutrophils: a reappraisal of the use of surface markers for neutrophil acti-
vation. Blood 78, 1105–1111.
Lacy, P., and Stow, J.L. (2011). Cytokine release from innate immune cells:
association with diverse membrane trafficking pathways. Blood 118, 9–18.
Liao,W., Lin, J.-X., and Leonard,W.J. (2013). Interleukin-2 at the crossroads of
effector responses, tolerance, and immunotherapy. Immunity 38, 13–25.
Lillard, J.W., Jr., Boyaka, P.N., Chertov, O., Oppenheim, J.J., and McGhee,
J.R. (1999). Mechanisms for induction of acquired host immunity by neutrophil
peptide defensins. Proc. Natl. Acad. Sci. USA 96, 651–656.
Mani, A., Roda, J., Young, D., Caligiuri, M.A., Fleming, G.F., Kaufman, P.,
Brufsky, A., Ottman, S., Carson, W.E., 3rd, and Shapiro, C.L. (2009). A phase
II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in
patients (PTS) with metastatic breast cancer (MBC) who have previously failed
trastuzumab. Breast Cancer Res. Treat. 117, 83–89.
Mu¨ller, I., Munder, M., Kropf, P., and Ha¨nsch, G.M. (2009). Polymorphonuclear
neutrophils and T lymphocytes: strange bedfellows or brothers in arms?
Trends Immunol. 30, 522–530.
Neckers, L.M., and Cossman, J. (1983). Transferrin receptor induction in
mitogen-stimulated human T lymphocytes is required for DNA synthesis and
cell division and is regulated by interleukin 2. Proc. Natl. Acad. Sci. USA 80,
3494–3498.
Overwijk, W.W. (2005). Breaking tolerance in cancer immunotherapy: time to
ACT. Curr. Opin. Immunol. 17, 187–194.
Park, S., Jiang, Z., Mortenson, E.D., Deng, L., Radkevich-Brown, O., Yang, X.,
Sattar, H., Wang, Y., Brown, N.K., Greene, M., et al. (2010). The therapeutic500 Cancer Cell 27, 489–501, April 13, 2015 ª2015 Elsevier Inc.effect of anti-HER2/neu antibody depends on both innate and adaptive immu-
nity. Cancer Cell 18, 160–170.
Pelletier, M., Micheletti, A., and Cassatella, M.A. (2010). Modulation of human
neutrophil survival and antigen expression by activated CD4+ and CD8+
T cells. J. Leukoc. Biol. 88, 1163–1170.
Pipkin, M.E., Sacks, J.A., Cruz-Guilloty, F., Lichtenheld, M.G., Bevan, M.J.,
and Rao, A. (2010). Interleukin-2 and inflammation induce distinct transcrip-
tional programs that promote the differentiation of effector cytolytic T cells.
Immunity 32, 79–90.
Poire´, X., Kline, J., Grinblatt, D., Zimmerman, T., Conner, K., Muhs, C.,
Gajewski, T., Van Besien, K., and Smith, S.M. (2010). Phase II study of immu-
nomodulation with granulocyte-macrophage colony-stimulating factor, inter-
leukin-2, and rituximab following autologous stem cell transplant in patients
with relapsed or refractory lymphomas. Leuk. Lymphoma 51, 1241–1250.
Pollard, J.W. (2004). Tumour-educated macrophages promote tumour pro-
gression and metastasis. Nat. Rev. Cancer 4, 71–78.
Rao, B.M., Driver, I., Lauffenburger, D.A., and Wittrup, K.D. (2005). High-affin-
ity CD25-binding IL-2 mutants potently stimulate persistent T cell growth.
Biochemistry 44, 10696–10701.
Repka, T., Chiorean, E.G., Gay, J., Herwig, K.E., Kohl, V.K., Yee, D., andMiller,
J.S. (2003). Trastuzumab and interleukin-2 in HER2-positive metastatic breast
cancer: a pilot study. Clin. Cancer Res. 9, 2440–2446.
Schneider-Merck, T., Lammerts van Bueren, J.J., Berger, S., Rossen, K., van
Berkel, P.H.C., Derer, S., Beyer, T., Lohse, S., Bleeker, W.K., Peipp, M., et al.
(2010). Human IgG2 antibodies against epidermal growth factor receptor
effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to
IgG1, only by cells of myeloid lineage. J. Immunology 184, 512–520.
Schwartz, R.H. (2003). T cell anergy. Annu. Rev. Immunol. 21, 305–334.
Siders, W.M., Shields, J., Garron, C., Hu, Y., Boutin, P., Shankara, S., Weber,
W., Roberts, B., and Kaplan, J.M. (2010). Involvement of neutrophils and nat-
ural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor
models. Leuk. Lymphoma 51, 1293–1304.
Sliwkowski, M.X., Lofgren, J.A., Lewis, G.D., Hotaling, T.E., Fendly, B.M., and
Fox, J.A. (1999). Nonclinical studies addressing the mechanism of action of
trastuzumab (Herceptin). Semin. Oncol. 26 (4, Suppl 12), 60–70.
Stagg, J., Johnstone, R.W., and Smyth, M.J. (2007). From cancer immunosur-
veillance to cancer immunotherapy. Immunol. Rev. 220, 82–101.
Stagg, J., Loi, S., Divisekera, U., Ngiow, S.F., Duret, H., Yagita, H., Teng,M.W.,
and Smyth, M.J. (2011). Anti-ErbB-2 mAb therapy requires type I and II inter-
ferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc. Natl.
Acad. Sci. USA 108, 7142–7147.
Suntharalingam, G., Perry, M.R., Ward, S., Brett, S.J., Castello-Cortes, A.,
Brunner, M.D., and Panoskaltsis, N. (2006). Cytokine storm in a phase 1 trial
of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355,
1018–1028.
van Elsas, A., Hurwitz, A.A., and Allison, J.P. (1999). Combination immuno-
therapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated
antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor
(GM-CSF)-producing vaccines induces rejection of subcutaneous and
metastatic tumors accompanied by autoimmune depigmentation. J. Exp.
Med. 190, 355–366.
Vasovic, L.V., Dyall, R., Clynes, R.A., Ravetch, J.V., and Nikolic-Zugic, J.
(1997). Synergy between an antibody and CD8+ cells in eliminating an estab-
lished tumor. Eur. J. Immunol. 27, 374–382.
Walunas, T.L., Lenschow, D.J., Bakker, C.Y., Linsley, P.S., Freeman, G.J.,
Green, J.M., Thompson, C.B., andBluestone, J.A. (1994). CTLA-4 can function
as a negative regulator of T cell activation. Immunity 1, 405–413.
Wang, S., Astsaturov, I.A., Bingham, C.A., McCarthy, K.M., vonMehren,M., Xu,
W.,Alpaugh,R.K., Tang,Y., Littlefield,B.A.,Hawkins, L.D., et al. (2012). Effective
antibody therapy induces host-protective antitumor immunity that is augmented
by TLR4 agonist treatment. Cancer Immunol. Immunother. 61, 49–61.
Ward, P.L., Koeppen, H., Hurteau, T., and Schreiber, H. (1989). Tumor anti-
gens defined by cloned immunological probes are highly polymorphic and
are not detected on autologous normal cells. J. Exp. Med. 170, 217–232.
Waugh, D.J.J., and Wilson, C. (2008). The interleukin-8 pathway in cancer.
Clin. Cancer Res. 14, 6735–6741.
Weiner, L.M., Dhodapkar, M.V., and Ferrone, S. (2009). Monoclonal antibodies
for cancer immunotherapy. Lancet 373, 1033–1040.
Weng, W.-K., and Levy, R. (2003). Two immunoglobulin G fragment C receptor
polymorphisms independently predict response to rituximab in patients with
follicular lymphoma. J. Clin. Oncol. 21, 3940–3947.
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., and Engert, A.
(1999). Cytokine-release syndrome in patients with B-cell chronic lymphocytic
leukemia and high lymphocyte counts after treatment with an anti-CD20
monoclonal antibody (rituximab, IDEC-C2B8). Blood 94, 2217–2224.
Wolpe, S.D., Sherry, B., Juers, D., Davatelis, G., Yurt, R.W., and Cerami, A.
(1989). Identification and characterization of macrophage inflammatory pro-
tein 2. Proc. Natl. Acad. Sci. USA 86, 612–616.Yang, J.C., Topalian, S.L., Schwartzentruber, D.J., Parkinson, D.R.,Marincola,
F.M., Weber, J.S., Seipp, C.A., White, D.E., and Rosenberg, S.A. (1995). The
use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment
of patients with metastatic renal cell carcinoma and melanoma. A phase I
study and a randomized prospective study comparing IL-2 alone versus IL-2
combined with PEG-IL-2. Cancer 76, 687–694.
Yu, A.L., Gilman, A.L., Ozkaynak, M.F., London, W.B., Kreissman, S.G., Chen,
H.X., Smith, M., Anderson, B., Villablanca, J.G., Matthay, K.K., et al.;
Children’s Oncology Group (2010). Anti-GD2 antibody with GM-CSF,
interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med. 363,
1324–1334.
Zhang, H., Zhang, S., Cheung, N.-K.V., Ragupathi, G., and Livingston, P.O.
(1998). Antibodies against GD2 ganglioside can eradicate syngeneic cancer
micrometastases. Cancer Res. 58, 2844–2849.Cancer Cell 27, 489–501, April 13, 2015 ª2015 Elsevier Inc. 501
